Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07392255 · ClinicalTrials.gov registry record · Phase 1
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
A Phase 1 study of Geographic Atrophy Secondary to Age-related Macular Degeneration, sponsored by Complement Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 3
- Study locations
NCT07392255: Recruiting Phase 1 study of Geographic Atrophy Secondary to Age-related Macular Degeneration, sponsored by Complement Therapeutics.
NCT07392255 is a Phase 1 study of Geographic Atrophy Secondary to Age-related Macular Degeneration that is actively recruiting participants, run by Complement Therapeutics. The registered enrollment target is 75 participants, below the 207-participant average among 4 other Geographic Atrophy Secondary to Age-related Macular Degeneration trials with a reported enrollment target (64% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07392255, a Phase 1 study of Geographic Atrophy Secondary to Age-related Macular Degeneration, is actively recruiting participants, sponsored by Complement Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD). Safety and efficacy will be measured at regular intervals for 2 years after which long-term safety will be assessed annually for up to 5 years.
Primary Outcome
Incidence and severity of ocular and non-ocular adverse events (AE)s and serious AEs (SAEs) up to Week 52 (Year 1)
Conditions Studied
Interventions
- GENETIC CTx001
Study Locations (3)
Indiana
- Midwest Eye Institute - Carmel
Nevada
- Sierra Eye Associates - Reno
Texas
- Retina Foundation of the Southwest - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-12-30 |
| Est. Completion | 2032-06-30 |
| Phase | Phase 1 |
What NCT07392255 shows while recruiting
NCT07392255 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 207-participant average among 4 other Geographic Atrophy Secondary to Age-related Macular Degeneration trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Geographic Atrophy Secondary to Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which CTx001 is the first listed.
NCT07392255 reports a single indexed study location in Indiana, Nevada, Texas.
Frequently Asked Questions
What is clinical trial NCT07392255 about?
NCT07392255 is a clinical study titled "An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)". This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD). Safety and efficacy will be measured at regular intervals for 2 years after which long-term safety will be assessed annually for up to 5 y...
What is the current status of trial NCT07392255?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2025-12-30. Estimated completion is 2032-06-30.
What conditions does trial NCT07392255 study?
This clinical trial studies the following conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration.
What interventions are being tested in trial NCT07392255?
The interventions under investigation include: CTx001 (GENETIC).
Who is sponsoring clinical trial NCT07392255?
This trial is sponsored by Complement Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07392255 being conducted?
This trial has 3 study locations across Indiana, Nevada, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy Secondary to Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
RECRUITING · Phase 2
-
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
RECRUITING · Phase 2
-
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI